Nevada
|
001-13305
|
95-3872914
|
(State
or other Jurisdiction
of
Incorporation)
|
(Commission
File Number)
|
(IRS
Employer
Identification
Number)
|
311
Bonnie Circle
Corona,
California
(Address
of principal executive offices)
|
92880
(Zip
Code)
|
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR
230.425)
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR
240.14d-2(b))
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR
240.13e-4(c))
|
99.1
|
Press
Release titled “Watson Pharmaceuticals Reports Second
Quarter 2008
Results” dated August
6, 2008.
|
Dated:
August
6, 2008
|
WATSON
PHARMACEUTICALS, INC.
|
|
By:
|
/s/
Mark
W. Durand
|
|
Mark
W. Durand
|
||
Senior
Vice
President - Chief
Financial Officer
|
||
Principal
Financial Officer
|
Exhibit
No.
|
Description
|
|
99.1
|
Press
Release titled “Watson Pharmaceuticals Reports Second
Quarter 2008
Results” dated August
6,
2008.
|